"In the past decades, CTP has been fused to a series of hormones, cytokines, and factors to elongate their half-lives. Compared with wild-type erythropoietin (EPO), the recombinant EPO-CTP produced by the fusion of CTP and the C-terminal gene of EPO showed significantly improved half-life and improved in vivo efficacy. FSH-CTP is the first CTP fusion protein to be included in clinical trials as a long-acting FSH to treat female infertility," cited from ****s://half-life-extension.creative-biolabs.com/carboxyl-terminal-peptide-ctp-based-half-life-extension-service.htm.
Like
Comment
Share
